Cite
HARVARD Citation
O'Reilly, E. et al. (2018). Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild‐type BRCA pancreatic ductal adenocarcinoma. Cancer. 124 (7), pp. 1374-1382. [Online].